Familial Breast Cancer Registry Program in Patients Referred to the Cancer Institute of Iran

被引:3
|
作者
Sabokbar, Tayebeh [1 ]
Khajeh, Elias [2 ,3 ]
Taghdiri, Foad [2 ,3 ]
Peyghambari, Vahideh [1 ]
Shirkoohi, Reza [1 ]
机构
[1] Canc Inst Iran, Canc Res Ctr, Dept Genet, Tehran, Iran
[2] Tehran Univ Med Sci, Students Sci Res Ctr, Tehran, Iran
[3] Tehran Univ Med Sci, ETDC, Tehran, Iran
关键词
Breast cancer; familial breast cancer; screening; registry program; BRCA1; MUTATIONS; EARLY-ONSET; HEREDITARY BREAST; HIGH-RISK; WOMEN; HISTORY; PREVALENCE; GENES; MANAGEMENT; GENETICS;
D O I
10.7314/APJCP.2012.13.6.2675
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Annually a considerable number of people die because of breast cancer, a common disease among women also in Iran. Identifying risk factors and susceptible people can lead to prevention or at least early diagnosis. Among susceptibility risks, 5-10% of patients have a family history predisposing factor which can influence the risk of incidence among the family. Having a registry program can be a more practical way to screen high risk families for preventive planning. Method: Based on inclusion criteria, a questionnaire was prepared and after a pilot study on a small number of patients, actual data were collected on 400 patients and processed in SPSS 16.0. Results: Totally, 28.2% of the patients were younger than 40 years old and 36.8% had the included criteria for familial breast cancer (FBC). 102 patient's samples could be compared for receptor presentation. Similar to other studies, the number of triple negative breast cancers increased as the age decreased. Conclusion: The high percentage of patients with FBC among 400 cases in this study demonstrates that in order to design an infrastructural diagnostic protocol and screening of patients with FBC, a precise survey related to frequency and founder mutations of FBC is needed nationwide.
引用
收藏
页码:2675 / 2679
页数:5
相关论文
共 50 条
  • [21] Multimodality breast cancer screening in women with a familial or genetic predisposition
    Trop, I.
    Lalonde, L.
    Mayrand, M. H.
    David, J.
    Larouche, N.
    Provencher, D.
    CURRENT ONCOLOGY, 2010, 17 (03) : 28 - 36
  • [22] Neoadjuvant Chemotherapy in Patients with HER2-Negative Breast Cancer: A Report from Clinical Breast Cancer Registry of Iran
    Roudini, Kamran
    Mirzania, Mehrzad
    Yavari, Tahereh
    Seyyedsalehi, Monireh Sadat
    Nahvijou, Azin
    Zebardast, Jayran
    Saadat, Mina
    Khajeh-Mehrizi, Ahmad
    ARCHIVES OF IRANIAN MEDICINE, 2024, 27 (04) : 206 - 215
  • [23] Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients
    Crawford, Beth
    Adams, Sophie B.
    Sittler, Taylor
    van den Akker, Jeroen
    Chan, Salina
    Leitner, Ofri
    Ryan, Lauren
    Gil, Elad
    van't Veer, Laura
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 163 (02) : 383 - 390
  • [24] Perceived risk and adherence to breast cancer screening guidelines among women with a familial history of breast cancer: A review of the literature
    Walker, Meghan J.
    Chiarelli, Anna M.
    Knight, Julia A.
    Mirea, Lucia
    Glendon, Gord
    Ritvo, Paul
    BREAST, 2013, 22 (04) : 395 - 404
  • [25] The mutation landscape of multiple cancer predisposition genes in Chinese familial/hereditary breast cancer families
    Dong, Li
    Zhang, Hailian
    Zhang, Huan
    Ye, Yingnan
    Cheng, Yanan
    Li, Lijuan
    Wei, Lijuan
    Han, Lei
    Cao, Yandong
    Li, Shixia
    Hao, Xishan
    Liu, Juntian
    Yu, Jinpu
    CANCER BIOLOGY & MEDICINE, 2022, 19 (06) : 850 - 870
  • [26] Exploring the requirements for a decision aid on familial breast cancer in the UK context: a qualitative study with patients referred to a cancer genetics service
    Iredale, Rachel
    Rapport, Frances
    Sivell, Stephanie
    Jones, Wendy
    Edwards, Adrian
    Gray, Jonathon
    Elwyn, Glyn
    JOURNAL OF EVALUATION IN CLINICAL PRACTICE, 2008, 14 (01) : 110 - 115
  • [27] Patterns of breast reconstruction in patients diagnosed with inflammatory breast cancer: The Dana-Farber Cancer Institute's Inflammatory Breast Cancer Program experience
    Nakhlis, Faina
    Regan, Meredith M.
    Chun, Yoon S.
    Dominici, Laura S.
    Caterson, Stephanie
    Bellon, Jennifer R.
    Warren, Laura
    Yeh, Eren D.
    Jacene, Heather A.
    King, Tari A.
    Overmoyer, Beth
    BREAST JOURNAL, 2020, 26 (03) : 384 - 390
  • [28] BRCA1 Status in Pakistani Breast Cancer Patients with Moderate Family History
    Moatter, Tariq
    Aban, Muniba
    Khan, Shaista
    Azam, Iqbal
    Pervez, Shahid
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2011, 21 (11): : 680 - 684
  • [29] Germline mutation landscape of Chinese patients with familial breast/ovarian cancer in a panel of 22 susceptibility genes
    Wang, Jiayu
    Li, Weiwei
    Shi, Yujian
    Huang, Yan
    Sun, Tao
    Tang, Lili
    Lu, Qing
    Lei, Qiumo
    Liao, Ning
    Jin, Feng
    Li, Hui
    Huang, Tao
    Qian, Jun
    Pang, Danmei
    Wang, Shusen
    Fan, Peizhi
    Wu, Xinhong
    Lin, Ying
    Qin, Haiyan
    Xu, Binghe
    CANCER MEDICINE, 2019, 8 (05): : 2074 - 2084
  • [30] Family history of breast cancer and all-cause mortality after breast cancer diagnosis in the Breast Cancer Family Registry
    Chang, Ellen T.
    Milne, Roger L.
    Phillips, Kelly-Anne
    Figueiredo, Jane C.
    Sangaramoorthy, Meera
    Keegan, Theresa H. M.
    Andrulis, Irene L.
    Hopper, John L.
    Goodwin, Pamela J.
    O'Malley, Frances P.
    Weerasooriya, Nayana
    Apicella, Carmel
    Southey, Melissa C.
    Friedlander, Michael L.
    Giles, Graham G.
    Whittemore, Alice S.
    West, Dee W.
    John, Esther M.
    BREAST CANCER RESEARCH AND TREATMENT, 2009, 117 (01) : 167 - 176